Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute – Waldenström Macroglobulinemia 1

References

• Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109:5096–5103.
   PubMed Web of Science ®Google Scholar
• Stone MJ, Pascual V. Pathophysiology of Waldenstrom's macroglobulinemia. Haematologica 2010;95:359–364.
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, . Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110–115.
   PubMed Web of Science ®Google Scholar
• Walsh SH, Laurell A, Sundstrom G, . Lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. Leuk Res 2005;29:729–734.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, . Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:1564–1577.
   PubMed Web of Science ®Google Scholar
• Kriangkum J, Taylor BJ, Treon SP, . Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res 2007;13:2005–2013.
   PubMed Web of Science ®Google Scholar
• Xu L, Sohani A, Arcaini L, . A somatic variant in MYD88 (L265P) revealed by whole genome sequencing differentiates lymphoplasmacytic lymphoma from marginal zone lymphomas. Blood 2011;118(Suppl. 1): Abstract 261.
   Google Scholar
• Ngo VN, Young RM, Schmitz R, . Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA, . Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 2003;30:220–225.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:273–277.
   PubMedGoogle Scholar
• Ioakimidis L, Patterson CJ, Hunter ZR, . Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:62–66.
   PubMedGoogle Scholar
• Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114:2375–2385.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, . Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, . Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–2055.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, . Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27: 3830–3835.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, . Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120–126.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Rawstron AC, Ashcroft AJ, . Assessment of bone marrow response in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:53–55.
   PubMedGoogle Scholar
• Barakat FH, Medeiros LJ, Wei EX, . Residual monotypic plasma cells in patients with Waldenstrom macroglobulinemia after therapy. Am J Clin Pathol 2011;135:365–373.
   PubMed Web of Science ®Google Scholar
• Drexler HG. Guide to leukemia-lymphoma cell lines. Braunschweig: DSMZ; 2010.
   Google Scholar
• Muirhead KA, Wallace PK, Schmitt TC, . Methodological considerations for implementation of lymphocyte subset analysis in a clinical reference laboratory. Ann NY Acad Sci 1986;468:113–127.
   PubMed Web of Science ®Google Scholar
• Matsui S, Faitar SL, Rossi MR, . Application of spectral karyotyping to the analysis of the human chromosome complement of interspecies somatic cell hybrids. Cancer Genet Cytogenet 2003;142:30–35.
   PubMed Web of Science ®Google Scholar
• Ried T, Koehler M, Padilla-Nash H, . Chromosome analysis by spectral karyotyping. In: Spector DL, Goldman RD, Leinwand LA, editors. Cells: a laboratory manual. New York: CSHL Press; 1997.
   Google Scholar
• Tang K, Fu DJ, Julien D, . Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 1999;96:10016–10020.
   PubMed Web of Science ®Google Scholar
• UCSC Genome Bioinformatics [Internet]. 2012. Available from: http://genome.ucsc.edu/index.html
   Google Scholar
• Schop RF, Van Wier SA, Xu R, . 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006;169: 150–153.
   PubMed Web of Science ®Google Scholar
• Berger F, Isaacson PG, Piris MA, . Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. In: Jaffe ES, Harris NL, Stein H, ., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 132–134.
   Google Scholar
• Quesnel B, Preudhomme C, Fenaux P. p16ink4a gene and hematological malignancies. Leuk Lymphoma 1996;22:11–24.
   PubMed Web of Science ®Google Scholar
• Bergh G, Ehinger M, Olofsson T, . Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation. Blood 1997;89:2938–2950.
   PubMed Web of Science ®Google Scholar
• Tam W, Gomez M, Chadburn A, . Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006;107:4090–4100.
   PubMed Web of Science ®Google Scholar
• Ray ME, Wistow G, Su YA, . AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci USA 1997;94:3229–3234.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Kucuk C, Deleeuw RJ, . Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009;23:1139–1151.
   PubMed Web of Science ®Google Scholar
• Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of Waldenstrom's macroglobulinemia. Leuk Res 2008;32:1669–1673.
   PubMed Web of Science ®Google Scholar